Corvus Pharmaceuticals, Inc. has announced an upsized underwritten public offering of 7,900,677 shares of its common stock at $22.15 per share, totaling approximately $175.0 million in gross proceeds. The company plans to use the net proceeds for working capital, research and development, sales, and marketing. The offering is expected to close on or about January 23, 2026. Jefferies and Goldman Sachs & Co. LLC are the lead book-running managers for the offering, with Mizuho and Ladenburg Thalmann & Co. Inc. also involved. The offering is being made under an effective shelf registration statement. Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on ITK inhibition for immune diseases and cancer.

Read more at GlobeNewswire: Corvus Pharmaceuticals Announces Pricing of Upsized Public